Product Overview
[Drug Name]
Generic Name: Cilnidipine Tablets
Trade Name: Fengyuan Cilnidipine Tablets 5mg*14 Tablets
Pinyin Code: FengYuan XiNiDiPingPian 5mg*14 Tablets
[Main Ingredient]
Cilnidipine
[Properties]
This product is a light yellow tablet.
[Indications/Main Functions]
Cilnidipine Tablets: For the treatment of hypertension.
[Precautions]
Elderly patients should start with a low dose and carefully observe the therapeutic response. When used in combination with digoxin, close attention should be paid to digoxin toxicity. Cilnidipine should be used with caution in patients with hepatic insufficiency, as plasma cilnidipine concentrations may increase. Cilnidipine is metabolized in the liver, so caution should be exercised when used concomitantly with the following medications: - Drugs that inhibit the CYP3A4 isoenzyme, such as cimetidine, ketoconazole, itraconazole, erythromycin, HIV protease inhibitors, and fluoxetine - CYP3A4 isoenzyme inducers, such as phenytoin, carbamazepine, and rifampicin - Drugs metabolized by the CYP3A4 isoenzyme, such as cyclosporine - Drugs that inhibit or induce the CYP2C19 isoenzyme - Drugs metabolized by the CYP2C19 isoenzyme, such as S-mephenytoin and omeprazole. Grape juice can increase cilnidipine plasma concentrations, so these two medications should not be used concomitantly. Women of childbearing age should use contraceptive measures during treatment. Use with caution in patients with congestive heart failure. Calcium channel blockers are not recommended for the following conditions: - Unstable angina - Myocardial infarction within the past month - Left ventricular outflow tract obstruction - Untreated congestive heart failure. Use with caution in patients with a history of serious adverse reactions to calcium channel blockers. Symptoms of sore throat may worsen at the start of treatment or when increasing the dose. Use with caution in patients with chronic renal insufficiency. Use with caution when combined with beta-blockers, especially in those with left ventricular dysfunction. During fentanyl anesthesia, it is recommended to discontinue nifedipine and other dihydropyridine derivatives 36 hours before surgery. Because sudden discontinuation of calcium channel blockers may worsen the condition, if discontinuation is necessary, the dose should be gradually reduced and symptoms should be fully observed before discontinuation. When the dose is reduced to 5 mg, alternative medications should be used. Discontinuation should be performed under the guidance of a physician.
[Drug Interactions]
This product is contraindicated in patients with allergies to any of the ingredients in this product.
[Pediatric Use]
No data are available for the use of this product in children, and its use in children is not recommended.
[Specifications]
5mg*14 tablets
[Dosage and Administration]
The initial adult dose is 5mg (one tablet) once daily, taken after breakfast. The dose can be increased based on the patient's clinical response, up to a maximum of 10mg (two tablets) once daily, taken after breakfast.
[Adverse Reactions]
Not yet known
[Contraindications]
This product is contraindicated in patients with hypersensitivity to any of the ingredients.
[Pharmacology and Toxicology]
This product is a lipophilic dihydropyridine calcium antagonist that binds to the dihydropyridine site of L-type calcium channels on vascular smooth muscle cell membranes, inhibiting the transmembrane influx of Ca2+ through these channels, thereby relaxing and dilating vascular smooth muscle and exerting a hypotensive effect. It also inhibits the release of norepinephrine from sympathetic nerve terminals and sympathetic nerve activity by inhibiting the transmembrane influx of Ca2+ through N-type calcium channels on sympathetic nerve cells.
